Windlas Biotech Ltd (WINDLAS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 1003519, "name": "Windlas Biotech", "stock_name": "Windlas Biotech", "full_name": "Windlas Biotech Ltd", "name_url": "stocks-analysis/windlas-biotech", "exchange": 0, "exchangecode": "", "country_id": 34, "currency": "INR", "cmp": "856.30", "chg": 19.4, "chgp": "2.32%", "dir": 1, "prev_price": "836.90", "mcapval": "1,752.00 Cr", "mcap": "Small Cap", "scripcode": 543329, "symbol": "WINDLAS", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "", "isin": "INE0H5O01029", "curr_date": "Feb 06", "curr_time": "", "bse_nse_vol": "90.66 k", "exc_status": "Active", "traded_date": "Feb 06, 2026", "traded_date_str": "2026 02 06", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-register-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/windlas-biotech-1003519-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "Windlas Biotech Gains 0.74%: 4 Key Factors Driving the Week’s Mixed Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-gains-074-4-key-factors-driving-the-weeks-mixed-momentum-3825928", "imagepath": "", "date": "2026-02-07 11:02:09", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>2 Feb:</strong> Stock opens at Rs.852.40, up 0.62% despite Sensex decline</p>\n <p><strong>3 Feb:</strong> Stock dips 1.61% amid Sensex rally</p>\n <p><strong>4 Feb:</strong> Stock rebounds 1.95% on improving technical momentum</p>\n <p><strong>5 Feb:</strong> Q3 results reveal steady growth but margin pressure; rating upgraded to Hold</p>\n <p><strong>6 Feb:</strong> Stock closes at Rs.853.45, up 1.98% amid mixed technical signals</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.847...." }, { "title": "Are Windlas Biotech Ltd latest results good or bad?", "link": "https://www.marketsmojo.com/news/result-analysis/are-windlas-biotech-ltd-latest-results-good-or-bad-3824952", "imagepath": "", "date": "2026-02-06 19:30:33", "description": "Windlas Biotech Ltd's latest financial results for Q3 FY26 reflect a complex operational landscape. The company reported net sales of ₹222.40 crores, marking an 18.93% year-on-year growth and a 5.86% sequential increase, indicating strong demand for its contract manufacturing services. This performance represents the seventh consecutive quarter of sequential revenue growth, underscoring the company's ability to capture market share and improve capacity utilization.\n\nHowever, the profitability metrics present a more nuanced picture. The net profit for the quarter was ₹17.80 crores, reflecting a year-on-year increase of 13.67%, but only a marginal sequential growth of 0.79%. The PAT margin experienced a contraction to 8.00% from 8.41% in the previous quarter, suggesting challenges in translating revenue growth into improved profitability. This compression in margins is attributed to rising operational expense..." }, { "title": "Windlas Biotech Ltd Faces Mixed Technical Signals Amid Mildly Bearish Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-faces-mixed-technical-signals-amid-mildly-bearish-momentum-3823705", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WindlasBiotechL_technicaldot_3823705.png", "date": "2026-02-06 08:03:33", "description": "Windlas Biotech Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, monthly signals suggest caution, reflecting a complex interplay of market forces that investors should carefully consider." }, { "title": "Windlas Biotech Q3 FY26: Steady Growth Marred by Margin Pressure and Weak Profitability", "link": "https://www.marketsmojo.com/news/result-analysis/windlas-biotech-q3-fy26-steady-growth-marred-by-margin-pressure-and-weak-profitability-3823330", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WindlasBiotech_quaterlyResult_3823330.png", "date": "2026-02-05 20:05:25", "description": "Windlas Biotech Ltd., a small-cap pharmaceutical contract development and manufacturing organisation (CDMO), reported mixed results for Q3 FY26 (October-December 2025), with net sales continuing their upward trajectory but profitability showing minimal sequential improvement. The company posted net profit of ₹17.80 crores for the quarter, representing a modest 0.79% quarter-on-quarter growth but a respectable 13.67% year-on-year increase. With a market capitalisation of ₹1,741 crores, the stock has faced significant headwinds, declining 17.27% over the past year and currently trading at ₹843.00, down 25.90% from its 52-week high of ₹1,137.60." }, { "title": "Windlas Biotech Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals", "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-upgraded-to-hold-as-technicals-improve-amid-mixed-financial-signals-3821895", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WindlasBiotechL_mojoScore_3821895.png", "date": "2026-02-05 08:28:59", "description": "Windlas Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable shift in its technical outlook and financial performance. The company’s improved technical indicators, steady financial trends, and fair valuation underpin this revised stance, despite some lingering concerns over long-term growth and recent underperformance relative to the broader market." }, { "title": "Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Market Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-technical-momentum-shifts-amid-mixed-market-signals-3821766", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WindlasBiotechL_technicaldot_3821766.png", "date": "2026-02-05 08:05:04", "description": "Windlas Biotech Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, signalling a potential consolidation phase. Recent technical indicators present a mixed picture, with weekly charts showing mild bullishness while monthly signals remain cautiously bearish. This nuanced technical landscape warrants close attention from investors seeking to gauge the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector." }, { "title": "Windlas Biotech Ltd is Rated Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/windlas-biotech-ltd-is-rated-sell-3816138", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/WindlasBiotechL_mojoScore_3816138.png", "date": "2026-02-02 10:10:47", "description": "Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 November 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals", "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-3808808", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/WindlasBiotechL_technicaldot_3808808.png", "date": "2026-01-29 08:03:14", "description": "Windlas Biotech Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from a Hold to a Sell rating by MarketsMOJO, the stock’s price action and key technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector." }, { "title": "Windlas Biotech Ltd Faces Bearish Momentum Amid Technical Downgrade", "link": "https://www.marketsmojo.com/news/stocks-in-action/windlas-biotech-ltd-faces-bearish-momentum-amid-technical-downgrade-3805010", "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/WindlasBiotechL_technicaldot_3805010.png", "date": "2026-01-27 08:03:20", "description": "Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop." } ], "total": 255, "sid": "1003519", "stock_news_url": "https://www.marketsmojo.com/news/windlas-biotech-1003519" }, "announcements": [ { "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Recording Of Conference Call", "datetime": "06-Feb-2026", "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Recording of Conference Call held on February 6 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation", "datetime": "05-Feb-2026", "details": "Investor Presentation for the Quarter and nine months ended December 31 2025", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release", "datetime": "05-Feb-2026", "details": "Windlas Biotech Limited Reports its 9M & Q3 FY26 Financial Results", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Windlas Biotech Ltd has declared <strong>116%</strong> dividend, ex-date: 21 Jul 25", "dt": "2025-07-21", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

2 Feb: Stock opens at Rs.852.40, up 0.62% despite Sensex decline

3 Feb: Stock dips 1.61% amid Sensex rally

4 Feb: Stock rebounds 1.95% on improving technical momentum

5 Feb: Q3 results reveal steady growth but margin pressure; rating upgraded to Hold

6 Feb: Stock closes at Rs.853.45, up 1.98% amid mixed technical signals

Week Open

Rs.847....

Read full news article

Are Windlas Biotech Ltd latest results good or bad?

2026-02-06 19:30:33

Windlas Biotech Ltd's latest financial results for Q3 FY26 reflect a complex operational landscape. The company reported net sales of ₹222.40 crores, marking an 18.93% year-on-year growth and a 5.86% sequential increase, indicating strong demand for its contract manufacturing services. This performance represents the seventh consecutive quarter of sequential revenue growth, underscoring the company's ability to capture market share and improve capacity utilization. However, the profitability metrics present a more nuanced picture. The net profit for the quarter was ₹17.80 crores, reflecting a year-on-year increase of 13.67%, but only a marginal sequential growth of 0.79%. The PAT margin experienced a contraction to 8.00% from 8.41% in the previous quarter, suggesting challenges in translating revenue growth into improved profitability. This compression in margins is attributed to rising operational expense...

Read full news article

Windlas Biotech Ltd Faces Mixed Technical Signals Amid Mildly Bearish Momentum

2026-02-06 08:03:33

Windlas Biotech Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly indicators, monthly signals suggest caution, reflecting a complex interplay of market forces that investors should carefully consider.

Read full news article

Windlas Biotech Q3 FY26: Steady Growth Marred by Margin Pressure and Weak Profitability

2026-02-05 20:05:25

Windlas Biotech Ltd., a small-cap pharmaceutical contract development and manufacturing organisation (CDMO), reported mixed results for Q3 FY26 (October-December 2025), with net sales continuing their upward trajectory but profitability showing minimal sequential improvement. The company posted net profit of ₹17.80 crores for the quarter, representing a modest 0.79% quarter-on-quarter growth but a respectable 13.67% year-on-year increase. With a market capitalisation of ₹1,741 crores, the stock has faced significant headwinds, declining 17.27% over the past year and currently trading at ₹843.00, down 25.90% from its 52-week high of ₹1,137.60.

Read full news article

Windlas Biotech Upgraded to Hold as Technicals Improve Amid Mixed Financial Signals

2026-02-05 08:28:59

Windlas Biotech Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable shift in its technical outlook and financial performance. The company’s improved technical indicators, steady financial trends, and fair valuation underpin this revised stance, despite some lingering concerns over long-term growth and recent underperformance relative to the broader market.

Read full news article

Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Market Signals

2026-02-05 08:05:04

Windlas Biotech Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a more sideways trend, signalling a potential consolidation phase. Recent technical indicators present a mixed picture, with weekly charts showing mild bullishness while monthly signals remain cautiously bearish. This nuanced technical landscape warrants close attention from investors seeking to gauge the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Read full news article

Windlas Biotech Ltd is Rated Sell

2026-02-02 10:10:47

Windlas Biotech Ltd is rated Sell by MarketsMOJO, with this rating last updated on 06 November 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Windlas Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

2026-01-29 08:03:14

Windlas Biotech Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade from a Hold to a Sell rating by MarketsMOJO, the stock’s price action and key technical indicators suggest a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Read full news article

Windlas Biotech Ltd Faces Bearish Momentum Amid Technical Downgrade

2026-01-27 08:03:20

Windlas Biotech Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to a more pronounced bearish trend. The stock’s recent price action, combined with mixed signals from MACD, RSI, and moving averages, suggests increasing caution for investors amid a challenging market backdrop.

Read full news article